Determinants of Bladder Cancer Recurrence Study (The DETER Study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02400944

Enrollment

600

Registered

2015-03-27

Start date

2015-03-01

Completion date

2027-03-01

Last updated

2026-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Keywords

MSK Tobacco Cessation Program, smoking exposure, 15-047

Brief summary

The purpose of this study is to learn how different lifestyle factors, such as cigarette smoking and body weight, change after a diagnosis of bladder cancer, and how they influence who gets a bladder cancer recurrence and who does not.

Interventions

BEHAVIORALquestionnaires

The study questionnaires (baseline and 2 follow-ups) will capture information on how modifiable factors, including the patients' smoking habits and body weight, have changed since last contact. RSA will conduct this interview at a time convenient to the patient either during a scheduled clinic visit or by telephone.

OTHERSaliva and/or urine sample

Patients will contribute approximately 5 mL of saliva at baseline, and at the time of their follow-up questionnaires. If the patient declines to contribute a saliva specimen, they can contribute approximately 10mL of urine. Urine is routinely collected from bladder cancer patients for clinically-related tests. We will also collect urine from every participant for whom the sample is not depleted by clinical tests at the end of the day. Saliva/urine specimens will be tested for cotinine which is regarded as the gold standard to detect recent smoking exposure and is widely used to identify active smokers in epidemiologic studies.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients ≥18 years old AND * Histologically-confirmed non-muscle invasive bladder cancer (NMIBC)

Exclusion criteria

* Patients are ineligible for the study if they have/had: * Histologically-confirmed NMIBC diagnosed \>36 months prior to enrollment * Cystectomy prior to enrollment * Any condition, which in the opinion of the primary MSK clinician or investigators precludes their ability to provide informed consent or comply with study procedures * Non English-speaking

Design outcomes

Primary

Measure	Time frame	Description
recurrence	1 year	will be defined as the presence of pathologically-confirmed NMIBC lesion \>8 weeks after diagnosis

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORHelena Furburg-Barnes, PhD

Memorial Sloan Kettering Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 8, 2026